Literature DB >> 35243940

miR-498 Targets UBE2T to Inhibit the Proliferation of Malignant Melanoma Cells.

Wen Cao1, Li Ni2, Pin Li3, Qi-Xia Wang4, Ming-Ming Li2, Shu-Hong Huang3,4, Ning-Ning Dang2.   

Abstract

Background: Malignant melanoma is a common malignant tumor and one of the tumors with the fastest growing incidence. The effect of microRNAs on the biological processing of malignant melanoma cells also have been reported. This study explores the ability of miR-498 to regulate the progression of malignant melanoma cells.
Methods: The expression of miR-498 was detected by RT-qPCR. The proliferation, invasion, and migration of malignant melanoma cells were measured by cell counting kit-8, clone formation, and transwell assays. Flow cytometry assay detected the percentage of apoptotic cells. Western blot was used to detect the expression of markers related to epithelial-mesenchymal transition. The correction of miR-498 and UBE2T was explored by dual-luciferase assay and Western blot.
Results: Overexpression of miR-498 inhibited the proliferation, invasion, migration, and induced cell apoptosis of M14 and A375 cells. In addition, the expression of epithelial-mesenchymal transition-related factors was altered by the overexpression of miR-498. miR-498 can directly target UBE2T 3'-UTR and inhibit UBE2T protein expression. The overexpression of UBE2T reversed the inhibitory effects of miR-498 on the progression of malignant melanoma cells. Furthermore, UBE2T mRNA was significantly highly expressed in malignant melanoma tissues. The high expression of UBE2T was associated with the poor overall survival rate of malignant melanoma patients. Conclusions: Altogether, our findings demonstrated that miR-498 significantly inhibited the proliferation, invasion, migration, and induced apoptosis of malignant melanoma cells and confirmed that miR-498 regulated malignant melanoma cell progression by targeting UBE2T.

Entities:  

Keywords:  EMT pathway; UBE2T; malignant melanoma; miR-498

Mesh:

Substances:

Year:  2022        PMID: 35243940      PMCID: PMC8902009          DOI: 10.1177/15330338221082431

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  16 in total

1.  Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma.

Authors:  Spyridon Gkalpakiotis; Petr Arenberger; Marketa Fridman; Monika Arenbergerova
Journal:  Dermatol Ther       Date:  2017-07-21       Impact factor: 2.851

2.  Downregulation of microRNA-498 in colorectal cancers and its cellular effects.

Authors:  Vinod Gopalan; Robert A Smith; Alfred K-Y Lam
Journal:  Exp Cell Res       Date:  2014-08-13       Impact factor: 3.905

3.  MicroRNA expression profiles associated with mutational status and survival in malignant melanoma.

Authors:  Stefano Caramuta; Suzanne Egyházi; Monica Rodolfo; Daniela Witten; Johan Hansson; Catharina Larsson; Weng-Onn Lui
Journal:  J Invest Dermatol       Date:  2010-04-01       Impact factor: 8.551

4.  Prognostic significance of miR-218 in human hepatocellular carcinoma and its role in cell growth.

Authors:  Kangsheng Tu; Chao Li; Xin Zheng; Wei Yang; Yingmin Yao; Qingguang Liu
Journal:  Oncol Rep       Date:  2014-08-07       Impact factor: 3.906

5.  UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma.

Authors:  Ying-Hua Pan; Mei Yang; Li-Ping Liu; Dan-Chun Wu; Ming-Yue Li; Shu-Guang Su
Journal:  Biochem Biophys Res Commun       Date:  2018-06-20       Impact factor: 3.575

6.  Primary malignant melanoma of the esophagus treated by esophagectomy and systemic chemotherapy.

Authors:  T Matsutani; M Onda; M Miyashita; N Hagiwara; Y Akiya; K Takubo; K Yamashita; K Sasajima
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

7.  Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1.

Authors:  Rachel E Bell; Mehdi Khaled; Dvir Netanely; Steffen Schubert; Tamar Golan; Amir Buxbaum; Maja M Janas; Benny Postolsky; Michael S Goldberg; Ron Shamir; Carmit Levy
Journal:  J Invest Dermatol       Date:  2013-08-09       Impact factor: 8.551

8.  UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells.

Authors:  Yan Qing Gong; Ding Peng; Xiang Hui Ning; Xin Yu Yang; Xue Song Li; Li Qun Zhou; Ying Lu Guo
Journal:  Oncol Lett       Date:  2016-10-10       Impact factor: 2.967

9.  The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer.

Authors:  Ryunosuke Kogo; Christine How; Naz Chaudary; Jeff Bruce; Wei Shi; Richard P Hill; Payam Zahedi; Kenneth W Yip; Fei-Fei Liu
Journal:  Oncotarget       Date:  2015-01-20

10.  miR-33a is downregulated in melanoma cells and modulates cell proliferation by targeting PCTAIRE1.

Authors:  Fangzhen Tian; Hongtu Wei; Hua Tian; Ying Qiu; Jian Xu
Journal:  Oncol Lett       Date:  2016-03-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.